Long-term oncologic outcomes following neoadjuvant therapy and transanal excision of T2 or T3 rectal cancer

Colorectal cancer is the third most commonly diagnosed cancer in the United States with over 140,000 new cases per year.1 Of these, approximately 40,000 represent rectal cancer.1 Surgical management of rectal cancers is typically comprised of neoadjuvant therapy and total mesorectal excision. Yet, total mesorectal excision carries significant risk for morbidity and mortality with complication rates up to 46% including perineal wound dehiscence, deep wound infection, anastomotic leak, fecal incontinence, and sexual dysfunction.

Source: American Journal of Surgery - August 29, 2020 Category: Surgery Authors: Sidrah Khan, Jesse Guardado, Brandon Mahler, Javier Salgado, James Celebrezze, David Medich, Jennifer Holder-Murray Source Type: research